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Supplementary Materials and Methods 29 
1. Production of mRNA reprogramming mRNA cocktail 30 
The transcript templates for reprogramming factors Oct4, Sox2, Klf4, c-Myc, Lin28 31 
were generated from the plasmids (from Addgene) by adding 120 T through tail 32 
PCR. Synthetic mRNA was generated in IVT reactions using a 4:1 ratio of ARCA 33 
cap analog to GTP to give a high percentage of capped transcripts. Complete 34 
substitution of 5m-CTP for CTP and Pseudo-UTP for UTP in the nucleotide 35 
triphosphate (NTP) mix was employed to reduce the immunogenicity of the RNA 36 
products. Cap analog and modified NTPs were purchased from Trilink 37 
Biotechnologies. A 2.5X NTP mix was prepared 38 
(ARCA:ATP:5m-CTP:GTP:Pseudo-UTP at 15:15:3.75:3.75:3.75 mM) to replace 39 
the standard NTPs provided with the MEGAscript T7 Kit (Ambion) used to perform 40 
IVT reactions. Each 40 uL IVT reaction comprised 16 uL NTP mix, 4 uL 10X T7 41 
Buffer, 16 uL DNA template and 4 uL T7 polymerase. Reactions were incubated 42 
4–6 hours at 37°C and treated with 2 uL TURBO DNase for a further 15 minutes 43 
at 37°C before being purified on MEGAclear (Ambion) spin columns; the RNA 44 
products being eluted in a volume of 100 uL. To remove immunogenic 5′ 45 
triphosphate moieties from uncapped transcripts, 10 uL of Antarctic Phosphatase 46 
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reaction buffer and 3 uL of Antarctic Phosphatase (NEB) were added to each prep. 47 
Phosphatase reactions were incubated for 30 minutes at 37°C and the IVT 48 
products were repurified. RNA yield was quantified by Nanodrop technology 49 
(Thermo Scientific), and the preps were subsequently adjusted to a standardized 50 
working concentration of 100 ng/uL by addition of TE pH 7.0 (Ambion). IVT 51 
product quality was checked with an RNA bioanalyzer. Cocktails were assembled 52 
by pooling preps representing the various RFs in the desired stoichiometric ratios. 53 
All reprogramming factors being equimolar except for Oct4 (3X molar 54 
concentration). 55 
 56 
2. Molecular Characterization of iPSCs 57 
Cells were fixed in 4% paraformaldehyde for 20 min. Washed cells were treated 58 
with 0.2% Triton X (Sigma) in PBS for 30 min. Cells were blocked with 3% BSA 59 
(Invitrogen) and 5% donkey serum (Sigma) for 2 hr at RT. Cells were stained in 60 
blocking buffer with primary antibodies at 4°C overnight. Cells were washed and 61 
stained with secondary antibodies) in blocking buffer for 3 hr at 4°C or for 1 hr at 62 
RT, protected from light. The images were taken with a LA confocal microscope. 63 
 64 
3. Teratoma formation 65 
Adult SCID mice were anesthesized with avertin, 0.5-1.0 ml IP (20 mg/ml) ~ 66 
125-240 mg/kg. 50 ul of iPS cell suspension (1 ×106 cells) were injected 67 
intramuscularly into the flanks (hamstring muscles) of the mice. After awaking 68 
from anesthesia, the mice were returned to their cage. After 8 weeks, the mice 69 
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were sacrificed by CO2 euthanisia and the tumors were histologically analyzed. 70 
 71 
4. Long-term maintenance of iPSCs  72 
iPSCs were routinely cultivated in standard hESC medium on Matrigel (BD 73 
Biosciences) -coated 6-well plates containing irradiated human feeder cells 74 
(ATCC CRL 2429). The hESC medium comprised KO DMEM/F12 supplemented 75 
with 20% Knockout Serum Replacement (Invitrogen), 10 ng/mL of bFGF 76 
(Invitrogen), 1x nonessential amino acids (Invitrogen), 0.1 mM β-Mercaptoethanol 77 
(Sigma), 1 mM L-glutamine (Gibco), plus 1% penicillin/streptomycin(Sigma). Cells 78 
were passaged every 7-9 days using 1 mg/ml collagenase IV (Invitrogen).  79 
 80 
5. Karyotyping 81 
2×105 cells were plated and grown in a slide flask (Thermo Scientific Nunc) for 24 82 
hours. Cells were treated with 10ng/ml colcemid (Sigma-Aldrich) for 50 min. Cells 83 
were then washed twice with PBS (Ca2+ and Mg2+ free), followed by a serial 84 
gradient fixation at 17%, 38%, 58%, and 100% fixation solution (1:3 of acetic 85 
acid:ethanol) for 5, 5, 5, and 40 min, respectively. Slides were dried on wet filter 86 
papers at room temperature. Karyotyping was performed by mounting the slide 87 
with DAPI-antifate (0.2 µg/ul) solution followed by imaging in an Axioplan 2 88 
microscope (Leica microsystem). Images were captured with IPlab Spectrum and 89 
analyzed with Quips CGH/Karyotyper (Vysis). 90 
6. Analysis of pluripotent markers in hiPS-MSCs by flow cytometry 91 
The hiPS-MSCs (passage 8 and 12) were harvested by trypsinization. Cells were 92 
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washed with PBS/2%FBS twice, followed by fixing with 1X FACSlysing solution 93 
for 10 min at room temperature. Fixed cells were permeabilized with FACSPerm 94 
solution for 10min at 4 °C and washed with PBS/2%FBS twice. Then cells (1X106 95 
per group) were stained with antibodies against OCT3/4 (BD PharmingenTM, Cat# 96 
560253), NANOG (BD PharmingenTM, Cat# 560791) or TRA-1-81 (BD 97 
PharmingenTM, Cat# 560793). For isotope controls, fluorochrome and 98 
concentration matched isotopes were used (IgG1 for OCT3/4 and NANOG, and 99 
IgM forTRA-1-81, BD Biosciences). Following two washes in PBS/2%FBS, cells 100 
were resuspended in 1% formaldehyde in PBS while vortex mixing. Cells were 101 
analyzed using a FACSAriaTM III (BD Biosciences) equipped with a 375 nm, 488 102 
nm, 561 nm, and 633 nm laser. For each sample 30,000 cells were collected and 103 
subsequently analyzed using FlowJo software (v. 9.3.3, TreeStar Inc., Ashland, 104 
OR).   105 
7. PCL-Hyaluronan-TCP scaffold fabrication and cell seeding  106 
PCL (MW = 50 kDa, Perstorp, UK) scaffolds were made by fused deposition 107 
modeling at a processing temperature of 100 0C with a BioScaffolder (SYS + ENG 108 
GmbH, Germany). Cylindrical scaffolds with a diameter of 4 mm were punched 109 
out from a 2 mm thick porous PCL mat using a sterile biopsy punch (Acuderm, 110 
Florida). To increase surface hydrophilicity, the scaffolds were etched in 5 M 111 
sodium hydroxide for 3 hours, rinsed in sterile water multiple times, and then in 112 
70% ethanol for sterilization. For fabrication of the PCL/Hyaluronan/TCP hybrids 113 
(PHT), PCL scaffolds were immersed in a 4.0 mg ml-1 hyaluronic acid solution 114 
(780 kDa, Lifecore Biomedical Inc., Lot P9805-9A) with β-TCP (Berkeley 115 
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advanced biomaterials Inc., Lot: TCPCH01) overnight at room temperature 116 
followed by freeze-drying (FTS, NJ, US). The weight ratio of hyaluronic acid to 117 
β-TCP is 10:1.  118 
PHT scaffolds were placed in 1% agarose-coated 24-well culture plates (one 119 
scaffold well-1). 10 µl of an iPS-MSCs suspension (1.25×107 cells / well) was 120 
dispensed onto scaffolds, giving a seeding number of 1.25×105 cells per scaffold. 121 
After 2 hours incubation, 1 ml basic medium consisting of DMEM-high glucose 122 
(Invitrogen), 2 mM L-Glutamine, 1% penicillin/streptomycin, and 10% FBS (Gibco), 123 
was added to each well and scaffolds were incubated overnight to allow the cells 124 
to adhere. In the control group, naked PCL scaffolds were seeded with 1.25×105 125 
cells per scaffold. For in vitro experiments, cell-seeded scaffolds were either 126 
stimulated with osteogenic medium or cultured in basal medium throughout the 127 
study for 3 weeks. Cell/scaffold constructs were collected on days 7, 14 and 21 for 128 
DNA, ALP, calcium assay, and gene expression analysis. Cell viability on PHT 129 
scaffolds were assessed by CellTrackerTM green staining on day 2 and day 7. 130 
Cellular distribution and morphology in scaffolds on day 21 were visualized in a 131 
scanning electron microscope (SEM). For in vivo experiments, cell-seeded 132 
scaffolds were pre-differentiated in osteogenic differentiation medium for 2 weeks 133 
before implantation. Media in all cultures were changed every 3-4 days. 134 
 135 
8. ALP/DNA/Calcium assay  136 
Four cellular-scaffold constructs from each group (PCL and PHT, basic and 137 
osteogenic medium) were transferred to 2 ml tubes with 400µl DMEM w/o Phenol 138 
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Red (Gibco 21063) and sonicated at intervals of 1 s on and 5 s off with amplitude 139 
of 50% (0.046 KJ) in a Bandelin Sonopuls sonicator (Buch & Holm, Denmark) for 140 
a total of 1 min. Aliquots of 60 µl were used for ALP activity assay. The remaining 141 
volume was supplemented with 10µl/tube Collagenase (Sigma C8176, 100mg/ml) 142 
and incubated in a 37 ˚C water bath for 3 hours. Seventeen micro liter Proteinase 143 
K (Sigma P2308, 20mg/ml) and 3µl Pen/Strep were then added and the samples 144 
were incubated at 45 ˚C for 20 hrs. Scaffold debris was spun down at 10.000 x g 145 
for 5 min. Aliquots of 90 µl were used for DNA quantification. The remaining 146 
volume was mixed with an equal volume of 1 M Acetic acid and left on a shaker 147 
overnight to dissolve the calcium deposition. The calcium amount was measured 148 
by Arsenazo III calcium assay. 149 
ALP activity was determined using a colorimetric endpoint assay measuring the 150 
enzymatic conversion of P-nitrophenyl phosphate (Sigma) to the yellowish 151 
product P-nitrophenol in the presence of ALP. Absorbance of P-nitrophenol was 152 
measured in a microplate reader (Victor3 1420 Multilabel Counter, PerkinElmer 153 
Life Sciences, Denmark) at wavelengths of 405 and 600 nm. Standards were 154 
prepared from P-nitrophenol (concentration range: 0-0.2 mM). Technical 155 
duplicates were used for each biological sample. ALP activity was expressed as 156 
nmol Nitrophenol/min/µgDNA.   157 
DNA contents were estimated by the Quant-iT™ PicoGreen® dsDNA assay 158 
(Invitrogen). Samples were diluted 1:10 in Tris–EDTA buffer. From each sample, 159 
2 x 50 µl were drawn and suspended with 50 µl of PicoGreen (diluted 1:200 in TE 160 
buffer). The mixtures were incubated for 5 min in the dark, and measured in a 161 
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96-well plate using a microplate reader (Victor3 1420 Multilabel Counter, 162 
PerkinElmer Life Sciences, Denmark). Samples were excited at 480 nm, and the 163 
fluorescence emission intensity was measured at 520 nm. Standards were 164 
prepared according to the manufacturer’s instruction (lambda DNA, concentration 165 
range: 0–1µg ml-1).  166 
Calcium contents were quantified by a colorimetric endpoint assay based on the 167 
complexformation of one Ca2+ ion with two Arsenazo III molecules to a 168 
blue-purple product (Diagnostic Chemicals Limited, Charlottetown, PE, Canada). 169 
The samples were diluted (1:2 on day 7 and 1:5 on day 14 and 1:10 on day 21) 170 
with double distilled water and aliquots of 20 µl were transferred to a 96-well plate. 171 
Arsenazo III solution (280 µl) was added and incubated for 10 min at room 172 
temperature. A standard dilution series of calcium ranging from 0 to 50 µg ml-1 173 
was prepared and Ca2+ concentration was quantified spectrophotometrically at 174 
650 nm. Calcium content was expressed as micrograms of Ca2+ per scaffold. 175 
 176 
9. Scanning electron microscope (SEM) and confocal imaging 177 
For SEM analysis, samples were fixed in 2.5% glutaraldehyde containing 0.1 M 178 
sodium cacodylate buffer (pH 7.4) and dehydrated in a graded series of ethanol 179 
(50–99%) before being transferred to an excicator for air-drying. Constructs were 180 
analysed using a low vacuum secondary electron detector (Nova NanoSEM 600, 181 
FEI Company) and element component of cell/scaffold construct was analyzed by 182 
energy dispersive X-ray spectrometer (EDX). 183 
To assess cell viability, the cell/scaffold constructs were incubated for 30 min in 184 
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DMEM containing 10 µM CellTrackerTM Green CMFDA (Invitrogen). The staining 185 
medium was replaced with fresh DMEM/10%FBS and the constructs were 186 
incubated for another 30 min at 37˚C. The cell/scaffold constructs were then 187 
rinsed in prewarmed PBS, fixed in 10% formalin for 5 min at room temperature, 188 
and stained with 1 µg/ml Hoechst 33258 (Sigma-Aldrich) in PBS for 20 min. Living 189 
cells were labelled green. Nuclei of the cells were stained with Hoechst, labelled 190 
red. Images were acquired using a laser scanning confocal microscope, 510 Meta 191 
(Zeiss Microimaging GmbH, Germany). The confocal settings (excitation, laser 192 
power, detector gain, and pinhole size) were same during all cell imaging. 193 
Separate channels and filters were used. Excitation/emission wavelengths were 194 
488 nm / 505-530 nm for CellTrackerTM Green and 405 nm / 420 nm for Hoechst. 195 
 196 
10. Q-PCR  197 
Total RNA were isolated from cell/scaffold constructs with an RNeasy Mini Kit 198 
(Qiagen) according to the manufacturer’s instructions, followed by quantification 199 
with a Nanodrop spectrophotometer and qualification by 1% agarose gel 200 
electrophoresis. Complete removal of genomic DNA from the RNA samples was 201 
achieved by treatment with DNase I (Invitrogen). For first-strand DNA synthesis, 202 
2µg of total RNA were reverse transcribed using a cDNA synthesis kit (Bio-Rad, 203 
Hercules, CA) in a final volume of 20 µl. Q-PCR primers for ALPL, COL1A1, OC, 204 
RUNX2, GAPDH, and BACT are listed in Supplementary Table 1. One µl (five 205 
times diluted) cDNA was used for Q-PCR analysis. Q-PCR was performed using 206 
the LightCycle 480 SYBR Green I Mater kit on LightCycler 480 (Roche) with the 207 
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following PCR program: 1 hold at 95 °C for 5 min; 50 cycles at 95 °C for 10 s, 60 208 
°C for 10 s, and 72 °C for 15 s (signal acquisition once). Relative gene expression 209 
was calculated using the 2−ΔΔct method after normalization to the reference gene 210 
GAPDH.  211 
 212 
11. Micro-CT analysis 213 
The implants from each mouse were scanned with a high resolution micro-CT 214 
system (vivaCT 40, Scanco Medical AG, Brüttisellen, Switzerland), resulting in 215 
three-dimensional (3D) reconstruction of cubic voxel sizes 10.5 × 10.5 × 10.5 µm3. 216 
Micro-CT images were segmented using techniques described in detail previously 217 
1 to obtain accurate 3D datasets of bone tissues. A mean optimal global threshold 218 
was applied to segment bone image datasets. Three-dimensional 219 
microarchitectural properties of implant bone tissue were analyzed. 220 
 221 
12. Histology analysis 222 
After micro-CT scanning, the scaffolds from each group were embedded in 223 
methylmethacrylate (MMA) and sectioned at 25-µm thickness with a cryostat. 224 
Sections were stained with Goldener’s Trichrom and Alizarin Red to visualize 225 
tissue morphology and evidence of new bone formation. 226 
 227 
13. Statistical analyses 228 
Results are presented as mean ± standard deviation (SD). Statistic analyses were 229 
performed using Stata software. The data of ALP/DNA/calcium content and gene 230 
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expression were analyzed by the paired sample test. Micro CT data were 231 
analyzed with one sample mean test. Significance was set at P<0.05. 232 
 233 
Reference: 234 
1. Ding, M., Odgaard, A. & Hvid, I. Accuracy of cancellous bone volume fraction measured by 235 
micro-CT scanning. Journal of biomechanics 32, 323-326 (1999). 236 
 237 
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Supplementary Figure Legends 241 
 242 
Supplementary Fig. 1. Immunostaining of OCT4, SOX2, and KLF4 expression in 243 
fibroblasts at 16 hours after modified mRNA transfection. OCT4, SOX2, and KLF4 244 
were stained in green. Nuclei were stained with DAPI (blue). Scale bar: 32 µm.    245 
 246 
Supplementary Fig. 2. ALP staining of iPS-MSCs after 7-days culturing in 247 
proliferation medium (a) or osteogenic medium (b). 248 
 249 
Supplementary Table 1. List of primers used for Q-PCR 250 
 251 
Supplementary Table 2. Quantitative comparison of microarchitectures between 252 
iPS-MSCs seeded scaffolds (PCL-MSC or PHT-MSC) and scaffolds without cells 253 
after implantation in nude mice for 12 weeks. BS/BV, bone surface to bone 254 
volume ratio (mm-1); BS/TV, bone surface to total volume ratio (mm-1); BV/TV, 255 
bone volume to total volume ration; SMI, structure model index; P-ratio, degree of 256 
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anisotropy; CD, connective density (mm-3); TbTh, trabecular thickness; TBSP, 257 
trabecular separation (mm); TbN, trabecular number. Results are given as Mean 258 
difference between iPS-MSCs seeded scaffolds (PCL-MSC or PHT-MSC) and 259 
scaffolds without cells (PCL or PHT), respectively, ± standard deviation. The P 260 
value represents one sample mean test against zero. Significant level p < 0.05.      261 
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Table S1
Gene Sequences (5’à3’) exons Amplicon (bp)
hALPL-F ATCAGGGACATTGACGTGATC
hALPL-R TTCCAGGTGTCAACGAGGTC
hCol1a1-F AGGGCCAAGACGAAGACATC
hCol1a1-R AGATCACGTCATCGCACAAC
hOC-F AGTCCAGCAAAGGTGCAGCC
hOC-R TCAGCCAACTCGTCACAGTC
hRunx2-F CAGTAGATGGACCTCGGGAA
hRunx2-R CCTAAATCACTGAGGCGGTC
hGAPDH-F TGGTATCGTGGAAGGACTCATGAC
hGAPDH-R ATGCCAGTGAGCTTCCCGTTCAGC
5-6 188
7-8 189
6-7 137
1-2 138
2-4 169
Table S2
Parameters Obs. MEAN±SD Pvalue
(OP=102)
BS/BV
PCL-MSC vs. PCL 4 13.335±24.725 0.359
PHT-MSC vs. PHT 4 -4.072±14.323 0.609
BS/TV
PCL-MSC vs. PCL 4 0.689±0.673 0.133
PHT-MSC vs. PHT 4 0.751±1.158 0.285
BV/TV
PCL-MSC vs. PCL 4 0.007±0.009 0.201
PHT-MSC vs. PHT 4 0.01±0.012 0.183
SMI
PCL-MSC vs. PCL 4 0.125±0.193 0.285
PHT-MSC vs. PHT 4 0.49±0.839 0.326
P-ratio
PCL-MSC vs. PCL 4 0.035±0.05 0.267
PHT-MSC vs. PHT 4 0.026±0.085 0.589
CD
PCL-MSC vs. PCL 4 -38.221±53.435 0.247
PHT-MSC vs. PHT 4 -47.132±74.107 0.293
TbTh
PCL-MSC vs. PCL 4 -0.001±0.003 0.603
PHT-MSC vs. PHT 4 -0.001±0.007 0.717
TBSP
PCL-MSC vs. PCL * 4 -0.037±0.003 <0.001
PHT-MSC vs. PHT 4 -0.05±0.053 0.163
TbN
PCL-MSC vs. PCL  * 4 1.178±0.253 0.002
PHT-MSC vs. PHT 4 1.375±1.404 0.145
